Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV

NCT02798692 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Cytomegalovirus Infection

Interventions

BIOLOGICAL: Low dose HB-101
BIOLOGICAL: Medium dose HB-101
BIOLOGICAL: High dose HB-101
BIOLOGICAL: Placebo

Sponsor

Hookipa Biotech GmbH

Collaborators

[object Object]